Biocon Closes $3bn Deal For Viatris Biosimilars
Cites ‘Historic Inflection Point’ For Biocon Biologics As Viatris Also Begins Transformation
Biocon has achieved a milestone after its Biocon Biologics subsidiary closed its $3bn deal to acquire the biosimilars business of longtime partner Viatris, in what management described as a “historic inflection point” for the Indian player.
You may also be interested in...
Viatris Is ‘Not Walking Away’ From Generics
After reporting sliding sales for both generics and complex generics in Q1, Viatris has nevertheless reaffirmed its commitment to the off-patent sector, highlighting in particular a planned launch this year of its Breyna rival to Symbicort.
In Quick Succession: Wave Of New Leaders Could Reshape Industry
With a number of top generics and biosimilars firms announcing new leaders over the past few months, the industry could be in for some strategic shifts as new faces take the helm at established off-patent players.
Three Filings Planned, Two Others On Track – But No Names From Viatris
Viatris’ CEO-in-waiting Scott Smith introduced himself during Viatris’ year-end earnings call.